Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Healing trauma with psychedelics with Saj Razvi— Part 1

Healing trauma with psychedelics with Saj Razvi— Part 1

FromBack from the Abyss: Psychiatry in Stories


Healing trauma with psychedelics with Saj Razvi— Part 1

FromBack from the Abyss: Psychiatry in Stories

ratings:
Length:
66 minutes
Released:
Nov 5, 2019
Format:
Podcast episode

Description

This is the first of a two part very special interview with Saj Razvi, the Director of Education at Innate Path in Denver, CO. Saj weaves together his three fascinating perspectives— that of a nationally recognized trauma expert, his own personal story of early childhood neglect and how this shaped everything else to come, and finally his long journey of healing the deepest wound a person can have, eventually coming to MDMA and then psilocybin at the latter part of his therapy journey.The episode starts with some foundational concepts in understanding trauma and its long term effects, then shifts to compare and contrast psychotherapy vs somatic therapies vs psychedelic assisted therapies (cannabis vs ketamine vs MDMA vs psilocybin).  Part 1 ends with Saj's life-changing MDMA therapy session and beautifully describes how MDMA might help people break through the dissociative legacy of complex PTSD and attachment trauma. MDMA-assisted psychotherapy for PTSD https://maps.orgInnate Path (ketamine and cannabis assisted therapy)https://www.innatepath.orgDissociation and traumahttps://www.innatepath.org/post/dissociation-psychedelic-therapyhttps://www.innatepath.org/post/why-mdma-psychedelic-therapy-may-not-work-for-youDr. Hhttps://www.craigheacockmd.comOn Twitter @bftapod
Released:
Nov 5, 2019
Format:
Podcast episode

Titles in the series (100)

How do we find a way out of the darkest depths of despair? Psychiatrist Dr. Craig Heacock hosts a deep dive into powerfully moving stories of hope and healing, as well as topical explorations of psychopharmacology, psychotherapy, and psychedelics.